ENB Therapeutics

Executive Summary

ENB Therapeutics is a private, pre-clinical stage biotechnology company developing first-in-class small molecule inhibitors targeting the endothelin B receptor (ETBR) for cancer immunotherapy. Its lead candidate, ENB-003, aims to overcome immune resistance by blocking ETBR-mediated suppression of T cell activity. In 2025, ENB announced a clinical collaboration with Coherus Biosciences and the Cancer Research Institute to evaluate ENB-003 in combination with toripalimab (LOQTORZI®) for ovarian cancer. This partnership validates the therapeutic potential of ENB-003 and provides resources for early clinical development. As a pre-clinical entity, ENB faces high technical and regulatory risk, but its novel mechanism and strategic collaboration offer a differentiated approach to enhancing checkpoint inhibitor efficacy. The company is actively pursuing IND-enabling studies and expects to initiate a Phase 1 trial in 2026.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 trial initiation for ENB-003 in solid tumors (potentially ovarian cancer)60% success
• Q2 2027Interim Phase 1 safety/efficacy data readout for ENB-003 + toripalimab combination30% success
• TBDPotential licensing or partnership agreement for ENB-003 in additional indications15% success